International stroke trial Switzerland: Some epidemiological data;International stroke trial Switzerland: Einige epidemiologische daten

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 50, 1999, Pages 1964-1969

  Mattle, H P ^a   Eicher Vella, E ^a   Bassetti, C ^a   Sandercock, P ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Dependency; International Stroke Trial; Mortality; Stroke; Stroke outcome

Indexed keywords

AGE; ARTICLE; DEPENDENT PERSONALITY DISORDER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; STROKE; SWITZERLAND;

AGED; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; SWITZERLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033582049     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sandercock P, Collins R, Counsell C, Farrell B, Peto R, Slattery J, for the International Stroke Trial Collaborative Group. The International Stroke Trial (1ST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 1997;349:1569-81.
2. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST; randomized placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.
3. Mattle HP. Neues in der Therapie und Prophylaxe des ischämischen Hirninfarkts. Schweiz Med Wochenschr 1997;127: 1663-6.
4. Bogousslavsky J. Antithrombotika und zerebrovaskuläre Prävention: Was gibt es Neues? Schweiz Med Wochenschr 1997;127:1941-4.
5. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
6. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333: 1581-7.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study Group (ECASS). JAMA 1995;274:1017-25.
8. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meider D, et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1948;352:1245-51.
9. Gönner F, Remonda L, Mattle HP, Sturzenegger M, Ozdoba C, Lövblad KD, et al. Local intraarterial thrombolysis in acute ischemic stroke. Stroke 1998;29:1894-2000.
10. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M, and the PROACT Investigators. PROACT: A phase II randomized trial of recombinant pro-urokinase b direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
11. Furlan AJ. Mitteilung an European Stroke Conference in Venedig. 9.4.1999.
12. Lyrer P, Schweikert K, Operschall C, Rickenbacher P, Ritz R, Steck AJ. Akuter Schlaganfall und Managed Care: Erfahrungen nach Einfühurung eines koordinierten Abklärugs-und Behandlungskonzepts. Schweiz Ärztezeitung 1999;80: 779-84.
13. Research dollars per death [front page, March]. Stroke 1998; 29.
14. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC., Masler JR, et al., and the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90.